NCT00108953View on ClinicalTrials.gov

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin

Multi kinase inhibitor plus Chemotherapy

DRUG

Doxorubicin/Placebo

Chemotherapy plus Placebo

Trial Locations (28)

10065

New York

14642

Rochester

33136

Miami

35294

Birmingham

37203

Nashville

55455

Minneapolis

70506

Lafayette

91342

Sylmar

94115

San Francisco

94121

San Francisco

98101

Seattle

350040

Krasnodar

420111

Kazan'

610002

Kirov

90211-1850

Beverly Hills

92668-3298

Orange

94304-1207

Palo Alto

07601

Hackensack

C1264AAA

Buenos Aires

Q8300HDH

Neuquén

Unknown

Buenos Aires

Hong Kong

M5G 2M9

Toronto

ME16 9QQ

Maidstone

W12 0HS

London

M20 4BX

Manchester

CH63 4JY

Bebington

B15 2TT

Birmingham

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY